Inhalation experts from the Woolcock Institute of Medical Research and the University of Sydney have launched a new company called Pulmatix to provide analytical services ranging from evaluation of APIs and formulations in respiratory cells to formulation and device design optimization. Directors of the new company are Paul M. Young, Daniela Traini, Judy Black, and Brian Oliver.
Young and Black commented, “We are in a unique position to offer a range of services, from molecular pharmacological studies of drug and excipient interactions at the lung interface, to advanced physical characterization, device development and aerosol evaluation. Our key management team has extensive experience in respiratory pharmacology, physicochemical characterization and aerosol formulation.”
The new company’s facilities include cellular biology and aerosol testing laboratories, and the team has more than 20 years of expertise in OINDP research and development, with a focus on nebulized solutions, dry powder inhalers (DPIs), and metered dose inhalers (MDIs).
Read the Pulmatix press release.
